(497) Development of a transdermal Edaravone patch as a novel parenteral therapeutic system for ALS

Introduction: Edaravone is used as an effective drug to reduce the progression of functional disability in amyotrophic lateral sclerosis (ALS), which is designated as an incurable disease.　It is used as an injectable and otherwise an oral suspension1).
However, there is a risk of aspiration involved, and restrictions are placed on fasting times and so on because of the influence of diet.
Here, we focused on the physical properties of edaravone and examined the feasibility of developing a transdermal therapeutic system (TTS) to improve the quality of life (QOL) of ALS patients and their caregivers in vitro.